Dashboard
Manage Tickers

ATXS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-verisk-analytics-analyst-turns-bearish-here-are-top-5-downgrades-for-thursday
This Verisk Analytics Analyst Turns Bearis...
10/16/2025 13:01:42

hc-wainwright--co-downgrades-astria-therapeutics-to-neutral
HC Wainwright & Co. Downgrades Astria Ther...
10/16/2025 10:47:44

HC Wainwright & Co. analyst Joseph Pantginis downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Neutral.

wedbush-downgrades-astria-therapeutics-to-neutral-lowers-price-target-to-13
Wedbush Downgrades Astria Therapeutics to ...
10/15/2025 15:15:04

Wedbush analyst Laura Chico downgrades Astria Therapeutics (NASDAQ:ATXS) from Outperform to Neutral and lowers the price tar...

jmp-securities-downgrades-astria-therapeutics-to-market-perform
JMP Securities Downgrades Astria Therapeut...
10/15/2025 11:18:47

JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics (NASDAQ:ATXS) from Market Outperform to Market Perform.

jefferies-downgrades-astria-therapeutics-to-hold-lowers-price-target-to-13
Jefferies Downgrades Astria Therapeutics t...
10/14/2025 18:18:58

Jefferies analyst Eun Yang downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Hold and lowers the price target from $3...

dow-jumps-over-300-points-citigroup-posts-upbeat-earnings
Dow Jumps Over 300 Points; Citigroup Posts...
10/14/2025 17:09:06

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate
BioCryst Says Astria Therapeutics $700 Mil...
10/14/2025 16:20:52

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

dominos-pizza-posts-upbeat-results-joins-astria-therapeutics-albertsons-companies-polaris-and-other-big-stocks-moving-higher-on-tuesday
Domino's Pizza Posts Upbeat Results, Joins...
10/14/2025 14:15:51

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 12:09:03

trading-halt-halt-status-updated-at-71500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:15:...
10/14/2025 11:15:04

Core News & Articles
BioCryst to Acquire Astria Therapeutics fo...
10/14/2025 11:02:17

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
10/14/2025 10:55:04

astria-therapeutics-initiates-phase-3-orbit-expanse-trial-of-navenibart-for-hae-announced-earlier-today
Astria Therapeutics Initiates Phase 3 ORBI...
10/08/2025 14:09:30

astria-therapeutics-to-present-new-data-on-its-drug-candidate-navenibart-at-2025-haei-regional-conference-emea-in-rome-italy
Astria Therapeutics To Present New Data On...
10/03/2025 12:04:05

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

astria-therapeutics-begins-opening-clinical-trial-sites-in-eu-and-may-begin-screening-participants-for-phase-3-alpha-orbit-trial-of-navenibart-for-hae-treatment
Astria Therapeutics Begins Opening Clinica...
10/02/2025 12:06:52

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

hc-wainwright--co-maintains-buy-on-astria-therapeutics-raises-price-target-to-20
HC Wainwright & Co. Maintains Buy on Astri...
09/17/2025 15:46:05

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and raises the price...

cantor-fitzgerald-reiterates-overweight-on-astria-therapeutics-maintains-49-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/17/2025 14:12:23

Cantor Fitzgerald analyst Steven Seedhouse reiterates Astria Therapeutics (NASDAQ:ATXS) with a Overweight and maintains $49 ...

astria-therapeutics-releases-initial-phase-1a-trial-results-for-star-0310-with-drug-showing-best-in-class-half-life-of-up-to-68-days-supporting-twice-yearly-dosing-demonstrated-durable-cytokine-inhibition-and-was-well-tolerated-with-no-adcc-related-side-effects
Astria Therapeutics Releases Initial Phase...
09/17/2025 12:07:48

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

astria-therapeutics-to-present-phase-1a-trial-of-star-0310-data-at-upcoming-eadv-congress-2025
Astria Therapeutics To Present Phase 1a Tr...
09/03/2025 12:14:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION